Shilpa Medicare has received Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) for its formulations manufacturing facility (SEZ unit) located at Jadcherla, Telangana, India which was inspected between November 11 and November 30, 2017. USFDA has determined that the inspection classification of this facility is VAI and accordingly EIR issued.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
